Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Price Target at $44.40

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $44.40.

Several research analysts have recently commented on OLMA shares. Citigroup increased their target price on Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. JPMorgan Chase & Co. upped their price target on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 18th. Stifel Nicolaus started coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, February 11th. They set a “buy” rating and a $48.00 price target on the stock. Wolfe Research began coverage on shares of Olema Pharmaceuticals in a research note on Friday. They issued a “peer perform” rating on the stock. Finally, Oppenheimer reissued an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $13.42 on Friday. Olema Pharmaceuticals has a twelve month low of $2.86 and a twelve month high of $36.26. The company has a market cap of $1.17 billion, a PE ratio of -7.22 and a beta of 1.93. The business’s 50 day moving average price is $21.35 and its two-hundred day moving average price is $19.17. The company has a quick ratio of 9.95, a current ratio of 9.95 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, analysts predict that Olema Pharmaceuticals will post -2.33 EPS for the current year.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.88, for a total transaction of $268,800.00. Following the transaction, the director directly owned 727,770 shares of the company’s stock, valued at approximately $19,562,457.60. The trade was a 1.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shane William Charles Kovacs sold 100,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $28.73, for a total value of $2,873,000.00. Following the completion of the sale, the insider owned 139,727 shares in the company, valued at $4,014,356.71. This trade represents a 41.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 217,311 shares of company stock worth $5,965,254 in the last 90 days. 16.36% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its position in shares of Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after purchasing an additional 2,168 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares in the last quarter. Torren Management LLC bought a new stake in Olema Pharmaceuticals in the fourth quarter worth approximately $44,000. Russell Investments Group Ltd. acquired a new position in Olema Pharmaceuticals in the third quarter valued at approximately $53,000. Finally, American Century Companies Inc. acquired a new position in Olema Pharmaceuticals in the second quarter valued at approximately $54,000. 91.78% of the stock is owned by institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.